Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
F-Dopa-PET Turnover in Early Parkinson's Disease
NCT00153972Phase 4Completed
- Sponsor
- Technische Universität Dresden
- Start
- Feb 2005
- Primary completion
- Sep 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of cabergoline in Parkinson's disease (PD) (2 arms), sponsored by Technische Universität Dresden. Primary endpoint: Difference of dopamine turnover rate measured by Fluoro-Dopa-PET in the putamen at 3 months. Started Feb 2005; status: completed.
02
Drugs
cabergoline
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT00153972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00153972.